IQVIA Aktie

 

Veteran IQVIA executive with nearly two decades in biopharma business development to lead Within3's commercial growth and client partnershipsBOSTON--(BUSINESS WIRE)--#AI--Within3, whose platform is trusted by all of the top 20 pharma companies to turn public data, private data, and expert networks into decision-ready evidence, today announced the appointment of Ira Daly as Chief Operating Officer. Daly joins Within3 after more than 18 years at IQVIA, where he built and led multi-billion-dollar business development teams serving pharma, biotech, and medtech companies across therapeutic areas. Most recently, Daly served as Senior Vice President, Offering Development at IQVIA, where he built a matrixed team of data and analytics experts and developed AI agents to improve how solutions reach and support customers. Previously, as Senior Vice President of Biotech and Midsize Business Development for the US and Canada, he led a large team of business development professionals and forged partnerships with biotec...

Margin expansion despite cost headwinds reveals how operational discipline is fueling profitability gains....

Revenue hit $4.4 billion with 8% growth; net new bookings surged 15% year over year....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

IQVIA (IQV) delivered earnings and revenue surprises of +3.09% and +1.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Tuesday, life sciences services company IQVIA Holdings Inc. (IQV) raised its adjusted earnings and revenue guidanc......

WASHINGTON (dpa-AFX) - IQVIA Holdings Inc. (IQV) reported earnings for its third quarter that Increases, from last yearThe company's earnings totaled $350 million, or $2.10 per share. This compare......

Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency GAAP Net Income $350 million, Adjusted EBITDA $1,032 million, up 8.7% year-over-year GAAP Diluted Earnings per Share $2.10, Adjusted Diluted Earnings per Share $3.34, up 11.3% year-over-year Commercial Solutions Revenue $1,789 million, up 6.9% year-over-year, up 7.9% at constant currency R&D Solutions Revenue $2,639 million, up 8.7% year-over-year, up 9.1% at constant currency R&D Solutions Net New Bookings $3.2 billion, up 15% year-over-year Operating Cash Flow $825 million, and Free Cash Flow $667 million, representing 120% of Adjusted Net Income Raising full-year 2026 guidance for Revenue, Adjusted EBITDA and Adjusted Diluted Earnings per Share Investor Day to be held on December 1, 2026 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industrie...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Veeva expands its IQVIA partnership with clinical operations software, boosting its market reach and growth prospects through wider adoption and integrated workflows....

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The......

RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications......

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus....

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: https://ir.iqvia.com. To participate in the conference call, interested parties must register in advance at: http://ir.iqvia.com. Following registration for the call, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and...

IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum....